報價延遲最少15分鐘:2025/01/11 17:14 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
338.91 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-25.03/5.55
|
|
企業價值
7.39B
|
| 資產負債 |
|
每股賬面淨值
35.63
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 17:14 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. |